Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

PURPOSE: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 µg, twice daily)+tiotropium (TIO; 5 µg, once daily) (SAL/FLU+TIO) and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mtibaa, Mondher, Gupta, Subhajit, Muthukumar, Madhusubramanian, Marvel, Jessica, Kaur, Harneet, Ishikawa, Ryotaro, Olivenstein, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650773/
https://www.ncbi.nlm.nih.gov/pubmed/34887668
http://dx.doi.org/10.2147/CEOR.S336915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650773/
https://www.ncbi.nlm.nih.gov/pubmed/34887668
http://dx.doi.org/10.2147/CEOR.S336915

Ejemplares similares